Skip to content

Titamed: what changed

Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

Titamed

BE 0866.408.156
NACE 21.209, Manufacture of basic pharmaceutical products and pharmaceutical preparations
financial year 2024 against 2025filed annual accounts (NBB)
Net result for the year
€642,536
2024 · €586,309+€56,227
Equity
€462,887
2024 · €420,351+€42,536
Cash
€161,819
2024 · €197,060-€35,240
Balance sheet total
€1.4m
2024 · €1.4m+€62,420

Largest movements

2024 to 2025
Assets
  • Current investments +€100,000

    up €100,000 (+66.7%), from €150,000 to €250,000

  • Tangible fixed assets -€57,246

    down €57,246 (-24.5%), from €233,210 to €175,963

    of which Plant, machinery and equipment: -€37,637

  • Receivables within one year +€36,502

    up €36,502 (+7.2%), from €506,740 to €543,242

    of which Trade receivables: +€48,153

  • Cash -€35,240

    down €35,240 (-17.9%), from €197,060 to €161,819

    mainly Contributions, distributions and other (-€600,000) and Current investments (-€100,000)

  • Stocks and contracts +€21,185

    up €21,185 (+7.5%), from €280,845 to €302,031

Equity and liabilities
  • Other debts +€98,339

    up €98,339 (+19.6%), from €501,661 to €600,000

  • Reserves +€42,536

    up €42,536 (+10.6%), from €401,751 to €444,287

  • Accrued charges and deferred income -€37,500

    down €37,500 (-17.6%), from €212,500 to €175,000

  • Debts after one year -€30,942

    down €30,942 (-66.3%), from €46,658 to €15,715

Income statement
  • Gross operating margin +€127,540

    up €127,540 (+10.2%), from €1.3m to €1.4m

  • Staff costs +€58,911

    up €58,911 (+15.5%), from €380,230 to €439,141

  • Taxes +€16,389

    up €16,389 (+8.1%), from €202,795 to €219,184

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 €586,309
Gross operating margin +€127,540
Staff costs -€58,911
Depreciation +€1,230
Other operating charges +€4,171
Financial income -€1,615
Financial charges +€201
Taxes -€16,389
Result 2025 €642,536

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations +€719,084
Investment -€124,021
Financing -€630,303
Cash 2024 €197,060
Net result for the year +€642,536
Depreciation +€81,267
Stocks and contracts -€21,185
Receivables within one year -€36,502
Deferred charges and accrued income +€2,780
Trade debts +€3,040
Tax, wage and social debts -€13,691
Other debts +€98,339
Accrued charges and deferred income -€37,500
Investment in fixed assets (net) -€24,021
Current investments -€100,000
Debts after one year -€30,942
Current portion of long-term debt +€639
Contributions, distributions and other -€600,000
Cash 2025 €161,819
Every line side by side 45 lines
Line Code 2024 2025 Change %
Total assets 20/58 €1,371,034 €1,433,454 +€62,420 +4.6%
Fixed assets 21/28 €233,210 €175,963 -€57,246 -24.5%
Tangible fixed assets 22/27 €233,210 €175,963 -€57,246 -24.5%
Plant, machinery and equipment 23 €169,685 €132,048 -€37,637 -22.2%
Other tangible fixed assets 26 €63,525 €43,915 -€19,609 -30.9%
Current assets 29/58 €1,137,825 €1,257,491 +€119,667 +10.5%
Stocks and contracts in progress 3 €280,845 €302,031 +€21,185 +7.5%
Stocks 30/36 €280,845 €302,031 +€21,185 +7.5%
Amounts receivable within one year 40/41 €506,740 €543,242 +€36,502 +7.2%
Trade receivables 40 €334,463 €382,616 +€48,153 +14.4%
Other amounts receivable 41 €172,277 €160,626 -€11,651 -6.8%
Current investments 50/53 €150,000 €250,000 +€100,000 +66.7%
Cash at bank and in hand 54/58 €197,060 €161,819 -€35,240 -17.9%
Deferred charges and accrued income 490/1 €3,180 €400 -€2,780 -87.4%
Total equity and liabilities 10/49 €1,371,034 €1,433,454 +€62,420 +4.6%
Equity 10/15 €420,351 €462,887 +€42,536 +10.1%
Contributions 10/11 €18,600 €18,600 = 0.0%
Reserves 13 €401,751 €444,287 +€42,536 +10.6%
Distributable reserves 133 €401,751 €444,287 +€42,536 +10.6%
Profit (loss) carried forward 14 - €0 =
Amounts payable 17/49 €950,684 €970,568 +€19,884 +2.1%
Amounts payable after more than one year 17 €46,658 €15,715 -€30,942 -66.3%
Financial debts 170/4 €46,658 €15,715 -€30,942 -66.3%
Amounts payable within one year 42/48 €691,526 €779,853 +€88,327 +12.8%
Current portion of amounts payable after more than one year 42 €30,303 €30,942 +€639 +2.1%
Trade debts 44 €91,232 €94,271 +€3,040 +3.3%
Suppliers 440/4 €91,232 €94,271 +€3,040 +3.3%
Taxes, remuneration and social security 45 €68,330 €54,639 -€13,691 -20.0%
Taxes 450/3 €29,165 €11,785 -€17,380 -59.6%
Remuneration and social security 454/9 €39,165 €42,853 +€3,688 +9.4%
Other amounts payable 47/48 €501,661 €600,000 +€98,339 +19.6%
Accrued charges and deferred income 492/3 €212,500 €175,000 -€37,500 -17.6%
Remuneration, social security and pensions 62 €380,230 €439,141 +€58,911 +15.5%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €82,497 €81,267 -€1,230 -1.5%
Other operating charges 640/8 €7,569 €3,398 -€4,171 -55.1%
Gross operating margin 9900 €1,251,820 €1,379,359 +€127,540 +10.2%
Operating profit (loss) 9901 €781,523 €855,553 +€74,030 +9.5%
Financial income 75/76B €10,125 €8,510 -€1,615 -16.0%
Recurring financial income 75 €10,125 €8,510 -€1,615 -16.0%
Financial charges 65/66B €2,545 €2,343 -€201 -7.9%
Recurring financial charges 65 €2,545 €2,343 -€201 -7.9%
Profit (loss) for the period before taxes 9903 €789,104 €861,720 +€72,616 +9.2%
Income taxes 67/77 €202,795 €219,184 +€16,389 +8.1%
Profit (loss) for the period 9904 €586,309 €642,536 +€56,227 +9.6%
Profit (loss) for the period to be appropriated 9905 €586,309 €642,536 +€56,227 +9.6%

Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 11 October 2026 via checked.be.